Ophthalmic

Flying Eyes Optics Launches Eyeglasses (Ophthalmic) Line

Retrieved on: 
Thursday, October 7, 2021

AUSTIN, Texas, Oct. 7, 2021 /PRNewswire/ --The Flying Eyes Optics brand launches the first line of Eyeglass (Ophthalmic) Frames specifically for use under helmets and headsets.

Key Points: 
  • AUSTIN, Texas, Oct. 7, 2021 /PRNewswire/ --The Flying Eyes Optics brand launches the first line of Eyeglass (Ophthalmic) Frames specifically for use under helmets and headsets.
  • While all of the original Flying Eyes sunglasses are prescription compatible, the new ophthalmic line allows customers to enjoy the same level of comfort with stronger prescription lenses, or beyond just sunny days.
  • Flying Eyes eyewear was invented by a pilot to be the world's most comfortable glasses while wearing helmets or headsets.
  • Their highly experienced engineers and designers work together to create its line of Flying Eyes eyewear that is supremely comfortable with or without a headset/helmet.

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference

Retrieved on: 
Monday, September 13, 2021

ONS-5010 has been rigorously tested to support our efforts to provide the first approved ophthalmic formulation of bevacizumab, said C. Russell Trenary III, President and Chief Executive Officer, Outlook Therapeutics.

Key Points: 
  • ONS-5010 has been rigorously tested to support our efforts to provide the first approved ophthalmic formulation of bevacizumab, said C. Russell Trenary III, President and Chief Executive Officer, Outlook Therapeutics.
  • Outlook Therapeutics wet AMD ONS-5010 clinical program for the planned BLA submission consists of three clinical trials, NORSE ONE, NORSE TWO, and NORSE THREE, all of which have now been completed.
  • Most recently, Outlook Therapeutics reported positive topline data from its NORSE TWO pivotal Phase 3 clinical trial.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.

Insights on the Ophthalmic Instrumentation Global Market to 2027 - Featuring Kowa, Leica Microsystems and Nidek Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, September 10, 2021

The "Ophthalmic Instrumentation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ophthalmic Instrumentation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Ophthalmic Disposables, one of the segments analyzed in the report, is projected to record a 3% CAGR and reach US$3.2 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 6.4% CAGR
    The Ophthalmic Instrumentation market in the U.S. is estimated at US$1.9 Billion in the year 2020.
  • In the global OCT Systems segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment.

 Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directors

Retrieved on: 
Wednesday, August 25, 2021

I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics Board of Directors, said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.

Key Points: 
  • I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics Board of Directors, said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.
  • Ms. Valorie previously served as Senior Vice President and General Manager of US Ophthalmology Rx and Surgical at Bausch + Lomb.
  • I am honored to join Visus Therapeutics Board of Directors and am looking forward to working with this talented and capable team, said Tracy Valorie.
  • Dwight Moxie is the General Counsel, Senior Vice President and Corporate Secretary at Revance Therapeutics.

Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial

Retrieved on: 
Thursday, August 19, 2021

At Neurophth, he will apply his extensive past experiencein growing and scaling businesses that apply gene therapy technology to Ophthalmology to improve the lives of under-served patients.

Key Points: 
  • At Neurophth, he will apply his extensive past experiencein growing and scaling businesses that apply gene therapy technology to Ophthalmology to improve the lives of under-served patients.
  • Dr. Li's previous positions include commercial leadership roles at top MNC pharmaceuticals including Bristol-Myers Squibb, Sanofi, Bayer, Novartis etc..
  • Within Novartis, he was a member of Lucentis best-in-class launch commercial launchteam as well as global Ophthalmology brand team.
  • Within Bayer, he led the company's successful launch of Eylea, built the commercial team and oversaw the strategic planning for the Ophthalmology business unit.

Worldwide Ophthalmic Operating Room Microscope Industry to 2027 - Players Include Carl Zeiss, Danaher and Topcon Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021

Aspects like surging the geriatric population and spurring efficacy of minimally invasive ophthalmic surgeries are expected to provide growth avenues for the global ophthalmic operating room microscope market.

Key Points: 
  • Aspects like surging the geriatric population and spurring efficacy of minimally invasive ophthalmic surgeries are expected to provide growth avenues for the global ophthalmic operating room microscope market.
  • Moreover, the growth of the ophthalmic operating room microscope market is expected to be fueled by the increased cases of several eye-related diseases around the world.
  • In addition, one of the main obstacles to the growth of the ophthalmic operating room microscope market is the high price of maintenance.
  • In addition, well set-up healthcare infrastructure and rise in ophthalmic surgeries have fuelled the demand for ophthalmic operating room microscopes in the region.

Merakris Announces Agreement With Miracles In Sight Eye Bank To Supply Opticyte® Repair Grafts to Eye Surgeons

Retrieved on: 
Tuesday, July 20, 2021

RESEARCH TRIANGLE PARK, N.C., July 20, 2021 (GLOBE NEWSWIRE) -- Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight (MIS) to supply Opticyte Amniotic Ophthalmic Repair Grafts to MIS-affiliated eye surgeons in three states.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., July 20, 2021 (GLOBE NEWSWIRE) -- Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight (MIS) to supply Opticyte Amniotic Ophthalmic Repair Grafts to MIS-affiliated eye surgeons in three states.
  • MIS is affiliated with more than 70 eye clinics in North and South Carolina and Texas that will now have ready access to Opticyte through the Merakris partnership.
  • Opticyte Amniotic Ophthalmic Repair Grafts provide a biological barrier intended to protect the corneal surface of the eye during healing and to help prevent the formation of scar tissue.
  • Through its active philanthropy program, MIS supports an eye bank in India, a mission in South America, and helps new eye banks create technical programs.

North American Ophthalmic Packaging Market (2020 to 2030) - Industry Analysis, Size, Share, Growth, Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021

Which is the most preferred material type for ophthalmic packaging in the North America market?

Key Points: 
  • Which is the most preferred material type for ophthalmic packaging in the North America market?
  • Which dose holds maximum market share in the North America ophthalmic packaging market?
  • The study enumerates vital market dynamics such as key drivers, challenges, and trends, along with opportunities in the North America ophthalmic packaging market.
  • Furthermore, forecast factors and forecast scenarios of the ophthalmic packaging market have been covered in the report to understand future prospects of the market.

PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for PAN-90806 for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asia

Retrieved on: 
Thursday, June 17, 2021

PanOptica, Inc. today confirms the licensing agreement with Zhaoke Ophthalmology Limited (HKEX Stock Code: 6622.HK) to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, in China, South Korea, and southeast Asia.

Key Points: 
  • PanOptica, Inc. today confirms the licensing agreement with Zhaoke Ophthalmology Limited (HKEX Stock Code: 6622.HK) to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, in China, South Korea, and southeast Asia.
  • PanOptica will support Zhaoke Ophthalmology through the provision of its expertise and know-how, as well as its existing supply of investigational product and/or active pharmaceutical ingredient.
  • Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to the research, development, and commercialization of therapies that address significant unmet medical needs.
  • Zhaoke Ophthalmology has received strong endorsement from blue-chip pre-IPO investors, including GIC, Hillhouse Capital, TPG, Loyal Valley Capital, OrbiMed, and Aier Eye Hospital.

Visionology Acquires Exclusive Worldwide License to SPARCS Contrast Sensitivity Testing Technology

Retrieved on: 
Thursday, June 3, 2021

NASHVILLE, Tenn., June 03, 2021 (GLOBE NEWSWIRE) -- Visionology, a subsidiary of Harrow Health, Inc. (Nasdaq:HROW), an ophthalmic-focused healthcare company, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its SPARCS technology available on Visionologys direct-to-consumer eyecare platform, Visionology.com .

Key Points: 
  • NASHVILLE, Tenn., June 03, 2021 (GLOBE NEWSWIRE) -- Visionology, a subsidiary of Harrow Health, Inc. (Nasdaq:HROW), an ophthalmic-focused healthcare company, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its SPARCS technology available on Visionologys direct-to-consumer eyecare platform, Visionology.com .
  • The need for SPARCS and other tools to help with the self-diagnosis of eye disease has never been greater.
  • The SPARCS contrast sensitivity test, which has undergone extensive testing in clinical trials, is a new eye test that focuses specifically on the ability to perceive contrast between light and dark.
  • For more information on the SPARCS contrast sensitivity test, go to sparcscontrastcenter.com .